Jean Jacques Bienaime, Director at Ascendis Pharma A/S (ASND), bought 2,000 shares at $245.85 ($493K) on 2026-08-14, disclosed to the SEC on 2026-08-18.
Director Jean Jacques Bienaime purchased 1,100 shares of Ascendis Pharma for $245.85 per share, marking the largest insider purchase in the company's history. This significant buy suggests insider confidence in the company's recent operational turnaround and commercial traction.
The stock is trading 11.59% below its 52-week high of $281.73, having declined 4.7% over the last 30 days despite a 3.14% gain over the last 90 days.
Q2 2026 earnings on August 13, 2026, which saw product revenue more than double year-over-year; the upcoming FDA decision on BioMarin's sNDA for Voxzogo on February 28, 2027, which could impact the competitive landscape for Yorvipath.
The stock is currently trading at a premium, with a recent article noting that the 24.0% gain over the past 30 days has raised the bar for what the fundamentals need to deliver next.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $245.85 | 1,100 | $270K | 54.9% |
| 2 | $246.91 | 900 | $222K | 45.1% |
| Total | $246.33 avg | 2,000 | $493K | 100% |
| Filing → |
| KROS | BUY | 2026-06-17 | $10K | — | Filing → |
| IMNM | BUY | 2026-06-09 | $204K | — | Filing → |
| IMNM | SELL | 2026-06-09 | $204K | — | Filing → |